Yaremchuk O, Posokhova K, Bandas I, Kurylo Kh, Tsybulska L
I. Horbachevsky Ternopil National Medical University.
Georgian Med News. 2019 Dec(297):135-140.
The aim of the research was to study the content of myelin basic protein (MBP) in the cerebellum and cerebral hemispheres of the BALB/c mice with experimental antiphospholipid syndrome as well as in cases of introduction of L-arginine and aminoguanidine. The research was performed using 50 female BALB/c mice, in which APS was simulated. L-arginine (25 mg/kg) and aminoguanidine (10 mg/kg) were used for correction. A Western blot analysis of the main myelin protein (antibodies against MBP) as well as a densitometric analysis of immunoreactive zones was carried out using the samples of the cerebellum and cerebral hemispheres of the control and experimental BALB/c mice. The increased content of MBP (18.4 kDa) in 256 times (p<0.001) in the tissue of the cerebral hemispheres of the BALB/c mice with antiphospholipid syndrome was evidenced compare to the control. It was found out that in the samples of the cerebral hemispheres, the content of MBP (18.4 kDa) increased in 4.8 times (p<0.001) with the use of L-arginine, in 10 times (p<0.001) - with aminoguanidine, in 13 times (p<0.001) - in cases of the combined use of L-arginine and aminoguanidine compare to the indices of the mice with antiphospholipid syndrome. It was proved that the content of MBP (95-110 kDa) in the samples of the cerebral hemispheres of the experimental animals did not significantly change compare to the control. In the cerebellum of the animals with antiphospholipid syndrome, it was established that the level of MBP (95-110 kDa) increased in more than 5 times (p<0.001), while the MBP (18.4 kDa) was found in very small amounts compare to the control. In cases of lone and combined use of nitric oxide synthesis modulators (L-arginine and aminoguanidine), there were no significant changes in the level of MBP (95-110 kDa) in the cerebellum of BALB/c mice with antiphospholipid syndrome compare to the indices of the BALB/c mice with antiphospholipid syndrome only.
该研究的目的是研究实验性抗磷脂综合征的BALB/c小鼠小脑和大脑半球中髓鞘碱性蛋白（MBP）的含量，以及给予L-精氨酸和氨基胍后的情况。研究使用了50只模拟抗磷脂综合征的雌性BALB/c小鼠。用L-精氨酸（25mg/kg）和氨基胍（10mg/kg）进行干预。使用对照和实验性BALB/c小鼠的小脑和大脑半球样本，对主要髓鞘蛋白进行蛋白质免疫印迹分析（抗MBP抗体）以及对免疫反应区进行光密度分析。与对照组相比，患有抗磷脂综合征的BALB/c小鼠大脑半球组织中MBP（18.4kDa）的含量增加了256倍（p<0.001）。研究发现，在大脑半球样本中，使用L-精氨酸时，MBP（18.4kDa）的含量增加了4.8倍（p<0.001），使用氨基胍时增加了10倍（p<0.001），联合使用L-精氨酸和氨基胍时增加了13倍（p<0.001），与患有抗磷脂综合征的小鼠指标相比。结果证明，与对照组相比，实验动物大脑半球样本中MBP（95-110kDa）的含量没有显著变化。在患有抗磷脂综合征的动物小脑中，发现MBP（95-110kDa）的水平增加了5倍以上（p<0.001），而与对照组相比，MBP（18.4kDa）的含量极少。在单独和联合使用一氧化氮合成调节剂（L-精氨酸和氨基胍）的情况下，与仅患有抗磷脂综合征的BALB/c小鼠指标相比，患有抗磷脂综合征的BALB/c小鼠小脑中MBP（95-110kDa）的水平没有显著变化。
